Can we use gonadotropin plasma concentration as surrogate marker for BMI-related incomplete estrogen suppression in breast cancer patients receiving anastrozole?

BACKGROUND: BMI has been suggested to impact on estrogenic activity in patients receiving anastrozole resulting in a reduced treatment efficacy in obese women. Current evidence in this regard is controversially discussed. Since estradiol is inversely correlated with gonadotropins it can be assumed t...

Descripción completa

Detalles Bibliográficos
Autores principales: Oberguggenberger, A., Meraner, V., Sztankay, M., Beer, B., Weigel, G., Oberacher, H., Kemmler, G., Czech, T., Holzner, B., Wildt, L., Sperner-Unterweger, B., Daniaux, M., Hubalek, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5371265/
https://www.ncbi.nlm.nih.gov/pubmed/28351392
http://dx.doi.org/10.1186/s12885-017-3208-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5371265/
https://www.ncbi.nlm.nih.gov/pubmed/28351392
http://dx.doi.org/10.1186/s12885-017-3208-6

Ejemplares similares